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Abstract 
Background: Risk estimates for the same patient can vary substantially among cardiovascular risk calculators and 
the reasons are not fully explained. We compared the relative risk increases for consistent risk factors changes across 
different cardiovascular risk calculators.
Methods: Five clinicians independently selected 16 calculators providing absolute risk estimations. Hypothetical 
patients were generated using a combination of seven risk factors [age, gender, smoking, blood pressure, high-den-
sity lipoprotein (HDL), total cholesterol and diabetes] dichotomized to high and low risk, generating 27 patients (128 
total). Relative risk increases due to specific risk factors were determined and compared.
Results: The 16 selected calculators were from six countries, used 5- and 10-year predictions, and estimated CVD 
or coronary heart disease risk. Across the different calculators for non-diabetic patients, changing age from 50 to 
70 produced average relative risk increases from 82 to 395 %, gender (female to male) 35–225 %, smoking status 
31–118 %, systolic blood pressure (120–160 mmHg) 16–124 %, total cholesterol (4–7 mmol/L) 51–302 % and HDL 
(1.3–0.8 mmol/L) 27–133 %. Similar results were found among diabetic patients. Some calculators appeared to have 
consistently higher relative risk increases over multiple risk factors.
Conclusions: Cardiovascular risk calculators weigh the same risk factors differently. For each risk factor, the relative 
risk increase from the calculator with the highest increase was generally three to eight times greater than the relative 
risk increase from the calculator with lowest increase. This likely contributes to some of the inconsistency in risk calcu-
lator estimation. It also limits the use of risk calculators in estimating the benefits of therapy.
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Background
Guidelines frequently encourage clinicians to use car-
diovascular disease (CVD) risk calculators to estimate 
a patient’s cardiovascular risk. The information is often 
used to classify patients into different risk categories to 
guide treatment decisions. Alternatively, calculators can 
provide absolute values to explain a patient’s estimated 
risk and discuss the benefits of differing therapies.
Although up to 74  % of primary care physicians who 
are specifically interested in cardiac disease may regu-
larly use CVD risk calculators [1], most studies show only 
22–48  % physicians regularly use risk calculators [2–4]. 
Some of the diverse reasons why calculators have not 
been universally adopted include lack of time, a feeling 
that the information is not helpful, a sense of oversimpli-
fication with risk tools, and an ability to predict risk sub-
jectively [2–4].
The inconsistency among CVD risk calculators [5–8] 
presents another possible limitation to their adoption and 
application. A review of 25 risk calculators found 33 % of 
the time different calculators assigned the same patient 
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to a different risk category [8]. For individual patients, 
the highest calculated absolute risk was, on average, five 
times higher than the lowest calculated absolute risk [8]. 
Focusing on diabetic or non-diabetic patients, cardiovas-
cular or coronary heart disease outcomes, and/or 5- or 
10-year time horizons made little difference in risk calcu-
lation agreement [8]. Only by focusing on CVD outcomes 
with a 10-year time horizon from Framingham-derived 
calculators did agreement approach 90 % [8].
Although inconsistency is common among risk cal-
culator estimations, the causes of the broad variation 
in absolute risk and frequent disagreement in risk cat-
egory assignment has not yet been described. As iden-
tified above, eliminating most of the variables appeared 
to improve agreement but did not fully explain the rea-
sons for disagreement. Our objective in this study was to 
determine how different risk calculators weigh individual 
cardiovascular risk factors (e.g. smoking).
Methods
This is a sub-study of risk factor increases from our ini-
tial study of CVD risk calculator agreement [8]. Selection 
of calculators and generation of hypothetical patients has 
been explained previously [8] but are reviewed below.
Calculator selection
We searched for and then independently selected a broad 
range of CVD and coronary heart disease (CHD) risk cal-
culators. Our goal was to identify representative sample of 
calculators from different countries, were or were not asso-
ciated with guidelines, used different data sources (Framing-
ham and others), used different formats (internet, paper and 
pencil, other) and calculated different outcomes durations 
(5 or 10 years). Originally, 20 calculators were selected and 
4 more were added to enhance diversity. In this sub-study, 
absolute risk estimates are needed to compare the relative 
risk increases that result from risk factor changes. There-
fore, we excluded seven calculators that did not provide 
absolute numbers. We also excluded the SCORE calculator 
as it only provided CVD mortality risk. Calculator inclusion 
and exclusion flow are presented in Fig. 1.
Patient variables
Seven risk factors common to all included calculators were 
age, gender, smoking status, diabetes, systolic BP, total 
cholesterol and HDL (or the total cholesterol/HDL ratio). 
Using a specific increase for each risk factor facilitated 
comparison across different calculators. We assigned two 
values for each risk factor: age 70 or 50; gender male or 
female; current smoking status yes or no; systolic BP 160 
or 120 mmHg; total cholesterol 7 or 4 mmol/L; HDL 0.8 or 
1.3 mmol/L. The two values for each seven risk factors cre-
ated 27 or 128 distinct patients.
Two authors independently completed the risk assess-
ment for all 128 hypothetical patients on each calcula-
tor. Ethics approval was not required for this study (as 
patients were hypothetical).
Analysis
Calculation of relative risk increase
To analyze the relative risk increase associated with each 
risk factor from each calculator, we performed individual 
risk factor analysis. For individual risk factor analysis (i.e., 
BP), we started with the lower risk option for that risk fac-
tor (120  mmHg) and then varied other risk factors (age, 
gender, smoking status, total cholesterol, HDL, and diabe-
tes) between high and low risk values to create 64 unique 
patients. For each patient, we increased the individual risk 
factor to the high-risk option (i.e. 160 mmHg) and recalcu-
lated the risks. This created pairs of identical patients with 
the same risk factors except for the individual risk factor 
analyzed, which was low-risk and high-risk for each patient 
in the pair. We then subtracted the lower-risk estimate from 
the higher-risk estimate, and divided the risk difference by 
the low-risk estimate. This created the patient’s relative risk 
increase for the specific individual risk factor.
Fig. 1 Flow of identification and selection of cardiovascular risk 
calculators for inclusion
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As an example, one patient pair in the BP risk fac-
tor analysis started with a 50  year old, male, smoker, 
non-diabetic, with a 7  mmol/L total cholesterol, and a 
0.8 mmol/L HDL. The low-risk patient had a 120 mmHg 
systolic BP while the high-risk was 160  mmHg. Edin-
burgh ASSIGN risk calculator estimated the low-risk 
patient’s risk (with the 120  mmHg BP) as 16.6  % and 
the high-risk patient’s risk (with the 160  mmHg BP) as 
25.3  %. The calculated relative risk increase would be 
(25.3–16.6 %)/16.6 % = 52.4 %.
Mean relative risk increase
The 128 patients provided 64 patient pairs in each indi-
vidual risk factor analysis. As some calculators do not 
estimate risk in diabetic patients, diabetic and non-dia-
betic patients were analyzed and presented separately. 
This halved the numbers again, leaving 32 diabetic and 
32 non-diabetic patient pairs. Therefore, each risk factor 
analysis had 32 relative risk increases for each calculator 
(among diabetics or non-diabetics). For each risk factor, 
we calculated the mean and standard deviation of the rel-
ative risk increase of each calculator. An example of the 
full formula is below.
For each risk factor, we ranked calculators from lowest to 
highest average relative risk increase. We also performed 
a sub-group analysis when permitted by the number of 
calculators per sub-group.
Results
Characteristics of the 16 calculators, 10 of which included 
diabetics, are summarized in Table 1 [9–21].
Comparison of risk increase due to specific risk factors
For non-diabetic patients, the mean relative risk increases 
for each risk factor and calculator are summarized on 
Table  2. The mean relative risk increase varied consider-
ably across calculators. For example, changing age from 50 
to 70 years, the average relative risk increase ranged from 
82 % for Edinburgh (Framingham, CHD) to 395 % for PRO-
CAM (Health Check), a 4.8 times difference. The ratios of 
highest average relative increase divided by lowest for the 
other risk factors was 6.4 for gender, 3.8 for smoking status, 
7.8 systolic BP, 5.9 total cholesterol and 4.9 for HDL.
For diabetic patients, the mean relative risk increases 
for each risk factor and calculator are summarized on 
Table  3. The ratios of highest average relative increase 
divided by lowest was 4.9 for age, 18.2 for gender, 3.5 for 
smoking status, 4.9 systolic BP, 8.1 total cholesterol, 4.9 
for HDL and 3.4 diabetic status.
Ranking of calculators by mean relative risk increase
For each risk factor, ranking of calculators based on 
mean relative risk increases from lowest to highest 
Table 1 Characteristics of included risk calculators
Risk calculator Composite 
outcome
Time frame Include  
diabetes
Design Country Cohort data used
Edinburgh (Framingham CVD) [9] CVD 10 (can choose) Yes Web UK Framingham
Edinburgh (ASSIGN) [9] CVD 10 Yes Web UK ASSIGN
Primary CVD risk calculator [10] CVD 10 Yes Web UK Framingham
Framingham Heart Study [11] CVD 10 Yes Web USA Framingham
QRISK2-2011 [12] CVD 10 Yes Web UK GP data in UK
Progetto Cuore [13] CVD 10 Yes Web Italy Longitudinal Italian Studies
JBS Assessor [14] CVD 10 No Download UK Framingham
Edinburgh (BNF) [9] CVD 10 No Web UK BNF
Reynolds Risk Score [15] CVD 10 No Web USA Reynolds
Australian absolute CVD risk [16] CVD 5 No (ranges for 
diabetes)
Web Australia National Vascular Disease 
Prevention Alliance
New Zealand know your numbers [17] CVD 5 Yes Web New Zealand Framingham
UKPDS risk engine [18] CHD 10 Yes Download UK UKPDS
i-phone STAT ATPIII lipid management [19] CHD 10 No i-phone USA Framingham
Edinburgh (Framingham CHD) [9] CHD 10 Yes Web UK Framingham
PROCAM health check [20] CHD 10 Yes Web Germany German Data
National cholesterol Education Program [21] CHD (MI) 10 No Web USA Framingham
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among non-diabetic and diabetic patients is provided 
in Table  4. Among the 16 non-diabetic calculators, 
Edinburgh (Framingham CVD), Edinburgh (ASSIGN), 
QRISK2-2011 and JBS Assessor had the lowest relative 
risk increase (ranked four or less) for three or four of the 
six risk factors. Reynolds Risk Score, iPhone ATPIII lipid 
management, PROCAM (Health Check), and National 
Cholesterol Education Program had the highest relative 
risk increases (ranked 13 or more) for three or four of the 
six risk factors.
Among the 10 diabetic calculators, Edinburgh 
(Framingham CVD), NZ Know Your Numbers, UKPDS, 
and Edinburgh (Framingham CHD) had the lowest rela-
tive risk increase (ranked three or less out of 10 calcula-
tors) for three or four of the seven risk factors. Progetto 
CUORE, UKPDS and PROCAM (Health Check) had 
Table 2 Average relative risk increase due to  specific risk factor for  each included risk calculator among  non-diabetic 
patients (relative risk increase ± standard deviation)

















Edinburgh (Framingham CVD) 112 ± 35 44 ± 12 70 ± 24 73 ± 25 51 ± 17 42 ± 14
Edinburgh (ASSIGN) 222 ± 53 35 ± 28 37 ± 8 49 ± 6 60 ± 21 27 ± 3
Primary CVD risk calculator 103 ± 31 56 ± 18 59 ± 15 69 ± 17 66 ± 20 56 ± 19
Framingham Heart Study 121 ± 23 91 ± 33 67 ± 11 83 ± 26 78 ± 13 41 ± 7
QRISK2-2011 335 ± 91 53 ± 20 57 ± 20 30 ± 17 51 ± 15 43 ± 14
Progetto CUORE 313 ± 30 141 ± 57 87 ± 27 75 ± 13 66 ± 26 29 ± 4
JBS Assessor 110 ± 35 48 ± 16 59 ± 15 43 ± 13 63 ± 19 54 ± 18
Edinburgh (BNF) 105 ± 31 56 ± 18 59 ± 13 71 ± 19 68 ± 22 56 ± 18
Reynolds Risk Score 344 ± 96 119 ± 82 83 ± 50 124 ± 44 89 ± 42 60 ± 35
Australian absolute CVD risk 153 ± 50 61 ± 20 95 ± 38 98 ± 37 65 ± 20 55 ± 19
New Zealand Know Your Numbers 154 ± 49 60 ± 19 95 ± 37 99 ± 37 60 ± 22 50 ± 21
UKPDS Risk Engine 182 ± 16 79 ± 8 31 ± 3 16 ± 2 77 ± 8 64 ± 6
i-phone STAT ATPIII lipid management 210 ± 228 225 ± 140 116 ± 110 72 ± 32 154 ± 124 61 ± 14
Edinburgh (Framingham CHD) 82 ± 32 64 ± 26 55 ± 16 51 ± 5 88 ± 26 73 ± 22
PROCAM Health Check 395 ± 204 114 ± 82 118 ± 27 35 ± 8 302 ± 67 133 ± 30
National Cholesterol Education Program 198 ± 203 201 ± 124 110 ± 125 69 ± 49 141 ± 129 61 ± 33
Overall average 196 ± 140 91 ± 80 75 ± 54 66 ± 37 92 ± 80 57 ± 30
Table 3 Average relative risk increase due to specific risk factor for each included risk calculator among diabetic patients 
(relative risk increase ± standard deviation)




















Edinburgh (Framingham CVD) 79 ± 28 11 ± 6 50 ± 18 52 ± 19 37 ± 13 31 ± 11 62 ± 33
Edinburgh (ASSIGN) 172 ± 47 15 ± 21 31 ± 10 40 ± 10 49 ± 20 23 ± 6 111 ± 28
Primary CVD risk calculator 96 ± 30 9 ± 10 52 ± 11 66 ± 16 51 ± 18 44 ± 16 60 ± 31
Framingham Heart Study 104 ± 24 62 ± 27 59 ± 14 73 ± 27 68 ± 17 35 ± 9 70 ± 18
QRISK2-2011 197 ± 65 37 ± 19 54 ± 20 28 ± 17 47 ± 14 40 ± 13 84 ± 37
Progetto CUORE 297 ± 35 164 ± 63 84 ± 28 72 ± 14 63 ± 25 28 ± 4 46 ± 8
New Zealand know your 
numbers
74 ± 13 11 ± 6 48 ± 7 49 ± 7 31 ± 6 25 ± 6 158 ± 123
UKPDS risk engine 167 ± 22 73 ± 11 29 ± 4 15 ± 2 72 ± 11 60 ± 9 50 ± 7
Edinburgh (Framingham CHD) 67 ± 30 17 ± 16 44 ± 13 41 ± 12 70 ± 20 58 ± 17 53 ± 31
PROCAM health check 327 ± 196 76 ± 65 101 ± 38 31 ± 11 251 ± 93 113 ± 42 88 ± 32
Overall average 158 ± 113 48 ± 56 55 ± 28 47 ± 24 74 ± 69 46 ± 30 78 ± 57
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the highest relative risk increases (ranked eight or more 
out of ten calculators) for three or four of the seven risk 
factors.
Sub-group comparison
Additional file  1: Table S1 provides the subgroup com-
parisons of the relative risk increase among non-diabetic 
calculators. Only two five-year calculators were identified 
and, therefore, were excluded. We did not complete sub-
group analysis on diabetic calculators, as the number of 
calculators was too small.
Among 16 calculators for non-diabetic patients, there 
were 14 10-year calculators, 5 for CHD and 9 for CVD. 
The average relative risk increases were higher for CHD 
compared to CVD for all risk factors except BP. Addition-
ally, the range of relative risk increases across the sample 
of calculators was higher for CHD compared to CVD for 
all risk factors except BP.
Among the 16 non-diabetic calculators, half were 
derived from the Framingham database and the other 
half from eight different databases. We excluded the 
5-year risk calculators and the CHD calculators to focus 
the comparison on the four Framingham-derived 10-year 
CVD calculators versus the five non-Framingham-
derived 10-year CVD calculators. The average relative 
risk increases for Framingham- and non-Framingham-
derived calculators were remarkably similar, except 
for age. The range of relative risk increases was higher 
for non-Framingham-derived calculators compared to 
Framingham-derived calculators. Therefore, although 
the pooled relative risk increases are similar, there is 
more variability between non-Framingham-derived 
calculators.
Sample patient
Figure  2 illustrates the relative risk increases for each 
calculator when individual risk factors are changed for 
Table 4 Ranking of each calculator by the average relative risk increase for each risk factor



















 Edinburgh (Framingham CVD) 5 2 9 11 1 4
 Edinburgh (ASSIGN) 12 1 2 5 4 1
 Primary CVD risk calculator 2 5 6 8 7 10
 Framingham Heart Study (CVD) 6 11 8 13 11 3
 QRISK2-2011 14 4 4 2 2 5
 Progetto CUORE 13 14 11 12 8 2
 JBS Assessor 4 3 7 4 5 7
 Edinburgh (BNF) 3 6 5 9 9 9
 Reynolds Risk Score 15 13 10 16 13 11
 NZ know your numbers 8 7 13 15 3 6
 Australian absolute CVD risk 7 8 12 14 6 8
 UKPDS 9 10 1 1 10 14
 iPhone ATP III lipid management 11 16 15 10 15 13
 Edinburgh (Framingham CHD) 1 9 3 6 12 15
 PROCAM (Health Check) 16 12 16 3 16 16
 National Cholesterol Education Program 10 15 14 7 14 12
Diabetic patients
 Edinburgh (Framingham CVD) 3 2 5 7 2 4 5
 Edinburgh (ASSIGN) 7 4 2 4 4 1 9
 Primary CVD risk calculator 4 1 6 8 5 7 4
 Framingham Heart Study (CVD) 5 7 8 10 7 5 6
 QRISK2-2011 8 6 7 2 3 6 7
 Progetto CUORE 9 10 9 9 6 3 1
 NZ know your numbers 2 3 4 6 1 2 10
 UKPDS 6 8 1 1 9 9 2
 Edinburgh (Framingham CHD) 1 5 3 5 8 8 3
 PROCAM (Health Check) 10 9 10 3 10 10 8
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a sample patient. The sample patient is a 50-year-old, 
female, non-diabetic, smoker, with 160  mmHg systolic 
BP, 7 mmol/L total cholesterol, and 0.8 mmol/L HDL. For 
example, changing total cholesterol from 4 to 7 mmol/L, 
the relative risk increase for Progetto CUORE was 42 and 
340 % for PROCAM.
Discussion
The mean relative risk increase for specific risk factors 
varied considerably among the CVD risk calculators. 
The highest average relative risk increase from a calcu-
lator was generally three to eight times greater than the 
calculator with the lowest average. For example, among 
non-diabetic risk calculators, an increase in total choles-
terol from 4 to 7 mmol/L resulted in an average relative 
risk of 302 % using the PROCAM Health Check Calcula-
tor compared to 51 % using the Edinburgh (Framingham 
CVD) calculator.
While there was a lot of variation among the over-
all group of calculators assessed, some calculators had 
remarkably similar results. For example, among non-
diabetic calculators, the average relative risk increases 
for JBS Assessor and Edinburgh (BNF) were frequently 
within 8 % for 5 of 6 risk factors (the other 28 %). Alter-
natively, considering the relative risk increases associated 
with smoking among non-diabetics, the lowest aver-
age relative risk increase was 31 % while the highest was 
118 %, a spread of 87 %. However, 11 of the 16 calcula-
tors had an average relative risk increase from 55 to 95 %, 
a difference of only 40 %. Similar results were found for 
gender that had a spread of 190 % (35–225 %), although 9 
of 16 calculators were within a 29 % spread and 13 of 16 
were within an 84 % spread.
Past research has shown frequent disagreement among 
risk calculators [5–8]. In our previous work, the disagree-
ment in risk categorization occurred 33 % of the time for 
paired risk calculator comparisons [8]. As well, the abso-
lute risk estimation varied considerably among different 
calculators, with the highest estimate five times greater 
than the lowest estimate for the same patient. In the pre-
vious study, subgroup testing found that limiting analy-
sis to 5- or 10-year outcomes or CVD or CHD outcomes, 
did not meaningfully improve agreement. Agreement 
only improved by limiting analysis to 10-year CVD out-
comes all derived from Framingham [8].
This is the first study to explore the reasons for differ-
ences in risk estimation. It is possible that poor agree-
ment could have arisen, in part, from different baseline 
risk. However, as our original study showed, the low-
est risk patient had remarkably similar risk estimation 
(≤4 %) across 14 different calculators. Alternatively, the 
weighting of risk factors among calculators could have 
been variable from patient to patient without any dis-
tinct pattern. However, we found large variation in how 
Fig. 2 Sample of relative risk increases for each risk factor for a 50-year-old, female, smoker, 160 mmHg systolic blood pressure, 7 mmol/L total 
cholesterol, 0.8 mmol/L HDL, non-diabetic
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calculators weight risk factors, with some calculators 
consistently providing more or less weight for a certain 
risk factors.
Why is there a difference in relative risk increase 
among the calculators? Compared to calculators using a 
CVD endpoint, the relative risk increase for all risk fac-
tors for CHD calculators was higher, except systolic BP. 
As CVD includes stroke (and systolic BP is an important 
risk factor for stroke), the higher relative risk increases 
for systolic BP in CVD as compared to CHD calculators 
makes sense. Compare this to total cholesterol which had 
an average relative risk increase of 152 % in CHD calcula-
tors versus 56 % in CVD calculators. Thus, some of the 
variability in relative risk increases result from the type of 
outcomes assessed.
The database used to derive the calculator appears 
to play some role in the variability of the relative risk 
increase. Calculators derived from non-Framingham 
databases varied more broadly than those derived from 
Framingham. This corresponds to the results of our 
first study showing that agreement was better among 
Framingham-derived calculators than among non-
Framingham-derived calculators [8]. As different popula-
tions have different risks and susceptibility to CVD, the 
variability with calculators derived from other databases 
could be anticipated. The Framingham-derived calcula-
tors must modify their model to better predict outcomes 
in different populations [22].
The variability in relative risk increases raises impor-
tant concerns around the use of calculators to assess the 
benefits of therapeutic interventions that target specific 
risk factors. Although it may seem reasonable to estimate 
potential therapy benefits simply by changing the risk 
factor in the calculator, there are a number of problems 
with this approach. Clinicians cannot assume that medi-
cations taking a systolic BP from 160 to 140 mmHg will 
yield the clinical benefits similar to the risk difference 
between 160 and 140 mmHg. Additionally, we know that 
some interventions that modify risk factors (atenolol [23], 
torcetrapib [24], rosiglitazone [25] to name a few) do not 
reduce CVD. Another potential failing in this approach, 
identified in this study, is the different weighting that cal-
culators appear to place on some risk factors. A change 
in systolic BP from 120 to 160 mmHg increases the aver-
age patient’s risk by 16  % (using the UKPDS engine) to 
124  % (Reynolds Risk Score), a greater than seven-fold 
difference. Some studies try to estimate the absolute car-
diovascular benefits from interventions designed to mod-
ify risk factors (e.g. naturopathic medicine for CVD risk 
[26]). By using changes in CVD estimations in this way, 
careful selection of risk calculator will result in dramatic 
difference in the calculated risks, and therefore perceived 
benefit of the intervention. For example, if the Reynolds 
Risk Score was used to estimate risk associated with BP 
changes, the estimated absolute cardiovascular risk ben-
efit would be much greater than if the UKPDS calcula-
tor was used. Researchers, journal editors and reviews 
should recognize that calculator choice in these studies 
could easily change the results in both a statistical and 
clinically significant way.
Limitations
Many of the limitations of this sub-study mirror those 
of our original study [8]. Although we used hypotheti-
cal patients, this did allow us to focus on specific changes 
in risks across a variety of patients, permitting easy cal-
culation of the relative risk increases due to risk factor 
change.
Conclusion
There is considerable variation among CVD risk calcu-
lators in the relative risk increase for each specific risk 
factor. The highest average relative risk increase for a 
calculator was 3.4–18.2 higher than the lowest average 
relative risk increase, depending on risk factor. Some cal-
culators more often produce higher relative risk changes 
(e.g. PROCAM) while others more often produce lower 
relative risk changes [e.g. Edinburgh (ASSIGN)]. How-
ever, there was also similarity among some of the cal-
culators. Although consistency could occur among 
calculators derived from different databases, 10-year 
CVD Framingham calculators appeared to have the most 
consistent relative risk increases. Researchers and clini-
cians should not assume risk differences from reductions 
in risk factors are reliable or consistent from one calcula-
tor to the next.
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